scholarly journals Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience

2013 ◽  
Vol 109 (5) ◽  
pp. 434-439 ◽  
Author(s):  
Meghan R. Forster ◽  
Omar M. Rashid ◽  
Matthew C. Perez ◽  
Junsung Choi ◽  
Tariq Chaudhry ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Single Institution ◽  
Hepatic Perfusion ◽  
Percutaneous Hepatic Perfusion

Approach to Metastatic Melanoma

2017 ◽  
Author(s):  
Alexandra Gangi ◽  
Jonathan S Zager
Keyword(s):  
Surgical Treatment ◽  
Metastatic Melanoma ◽  
Distant Metastasis ◽  
Systemic Therapy ◽  
Newly Diagnosed ◽  
Hepatic Perfusion ◽  
Melanoma Patients ◽  
Almost All ◽  
In Transit ◽  
Percutaneous Hepatic Perfusion

Over several decades, the incidence of melanoma has steadily risen. Although a minority of newly diagnosed melanoma patients present with distant metastasis at initial diagnosis, approximately 30% of patients eventually develop metastatic disease as a consequence of disease progression. Although almost all organs can be involved, the most frequent sites of disease are either local or regional recurrences. This review outlines surgical treatment of recurrent or metastatic melanoma, including regional therapies, as well as management with systemic therapy.  This review contains 5 figures, 6 tables and 66 references Key words: in-transit disease, limb infusion, metastatectomy, metastatic melanoma, percutaneous hepatic perfusion, regional therapy, systemic therapy

Approach to Metastatic Melanoma

2017 ◽  
Author(s):  
Alexandra Gangi ◽  
Jonathan S Zager
Keyword(s):  
Surgical Treatment ◽  
Metastatic Melanoma ◽  
Distant Metastasis ◽  
Systemic Therapy ◽  
Newly Diagnosed ◽  
Hepatic Perfusion ◽  
Melanoma Patients ◽  
Almost All ◽  
In Transit ◽  
Percutaneous Hepatic Perfusion

Over several decades, the incidence of melanoma has steadily risen. Although a minority of newly diagnosed melanoma patients present with distant metastasis at initial diagnosis, approximately 30% of patients eventually develop metastatic disease as a consequence of disease progression. Although almost all organs can be involved, the most frequent sites of disease are either local or regional recurrences. This review outlines surgical treatment of recurrent or metastatic melanoma, including regional therapies, as well as management with systemic therapy.  This review contains 5 figures, 6 tables and 66 references Key words: in-transit disease, limb infusion, metastatectomy, metastatic melanoma, percutaneous hepatic perfusion, regional therapy, systemic therapy

100. A single institution experience with percutaneous hepatic perfusion for unresectable melanoma or sarcoma to the liver

2014 ◽  
Vol 40 (11) ◽  
pp. S47-S48 ◽  
Author(s):  
O.M. Rashid ◽  
J. Choi ◽  
T. Chaudhry ◽  
J. Sweeney ◽  
P. Werner ◽  
...  
Keyword(s):  
Single Institution ◽  
Hepatic Perfusion ◽  
Percutaneous Hepatic Perfusion

scholarly journals Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma

2020 ◽  
Vol 146 (11) ◽  
pp. 3003-3012 ◽  
Author(s):  
Leon Schönfeld ◽  
Jan B. Hinrichs ◽  
Steffen Marquardt ◽  
Torsten Voigtländer ◽  
Cornelia Dewald ◽  
...  
Keyword(s):  
Medical School ◽  
Liver Tumors ◽  
Interventional Procedure ◽  
Venous Blood ◽  
Hepatic Metastases ◽  
Ocular Melanoma ◽  
Liver Malignancies ◽  
Hannover Medical School ◽  
Hepatic Perfusion ◽  
Percutaneous Hepatic Perfusion

Abstract Background Chemosaturation with percutaneous hepatic perfusion (CS-PHP; Hepatic CHEMOSAT® Delivery System; Delcath Systems Inc, USA) is a novel interventional procedure, which delivers high doses of melphalan directly to the liver in patients with liver tumors while limiting systemic toxicity through hemofiltration of the hepatic venous blood. We have previously shown promising efficacy for patients with ocular melanoma (OM) and cholangiocarcinoma (CCA) within our single-center and multi-center experiences. The aim of this study was to analyze the safety and efficacy of CS-PHP after 141 treatments at Hannover Medical School, Germany. Methods Overall response rates (ORR) were assessed according to Response Evaluation Criteria In Solid Tumors (RECIST1.1). Median Overall survival (mOS), median progression-free survival (mPFS), and median hepatic PFS (mhPFS) were analyzed using the Kaplan–Meier estimation. Results Overall, 60 patients were treated with CS-PHP in the salvage setting from October 2014 until January 2019 at Hannover Medical School with a total of 141 procedures. Half of the patients were patients with hepatic metastases of ocular melanoma (OM) (n = 30), 14 patients had CCA (23.3%), 6 patients had hepatocellular carcinoma (10%), and 10 patients were treated for other secondary liver malignancies (16.7%). In total, ORR and disease stabilization rate were 33.3% and 70.3% (n = 25), respectively. ORR was highest for patients with OM (42.3%), followed by patients with CCA (30.8%). Independent response-associated factors were normal levels of lactate dehydrogenase (odds ratio (OR) 13.7; p = 0.015) and diagnosis with OM (OR 9.3; p = 0.028). Overall, mOS was 9 months, mPFS was 4 months, and mhPFS was 5 months. Patients with OM had the longest mOS, mPFS, and mhPFS with 12, 6, and 6 months, respectively. Adverse events included most frequently significant, but transient, hematologic toxicities (80% of grade 3/4 thrombopenia), less frequently hepatic injury up to liver failure (3.3%) and cardiovascular events including two cases of ischemic insults (5%). Conclusion Salvage treatment with CS-PHP is safe and effective particularly in patients OM and CCA. Careful attention should be paid to possible, serious hepatic, and cardiovascular complications.

Sign in / Sign up

Export Citation Format

Share Document